JAZZ
$138.25
Jazz Pharma Plc
($.24)
(.17%)
JAZZ
Earnings Whisper ®
N/A
4th Quarter December 2018
Consensus:  $2.65
Revenue:  $474.70 Mil
Tuesday
Feb 5
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when JAZZ reports earnings?
Beat
Meet
Miss

Where is JAZZ's stock price going from here?
Up
Flat
Down
Stock chart of JAZZ
Analysts
Summary of analysts' recommendations for JAZZ
Score
Grade
Pivots
Resistance
$146.63
$144.59
$141.42

$139.37

Support
$136.20
$134.16
$130.99
Tweet
Growth
Description
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and acquisition/in-licensing activities and to utilize our specialty sales force to promote products in our target markets. They apply novel formulations and drug delivery technologies to known drug compounds, and compounds with the same mechanism of action or similar chemical structure as marketed products, to improve patient care by improving efficacy, reducing adverse side effects or increasing patient compliance relative to existing therapies. Based in Palo Alto, California, the company is committed to working closely with patients, patient advocacy groups and healthcare professionals.